Secarna Pharmaceuticals GmbH & Co. KG

  • Land: Deutschland

Nachricht vom 10.09.2019 | 14:00

Secarna Pharmaceuticals enters into oncology research agreement with global top 10 pharmaceutical company

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Agreement

10.09.2019 / 14:00
The issuer is solely responsible for the content of this announcement.


Secarna Pharmaceuticals enters into oncology research agreement with global top 10 pharmaceutical company

  • Secarna to provide leading industry partner with LNAplusTM based antisense oligonucleotides to support research and development in the field of oncology
  • First research agreement with large global pharmaceutical company follows several successful collaborations with specialty pharmaceutical and biotech players in 2018

Munich/Martinsried, Germany, September 10, 2019 - Secarna Pharmaceuticals ("Secarna"), a new breed of biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, today announced that the Company has entered into an research agreement with a global pharmaceutical company to support research and discovery in the field of oncology. Under the terms of the agreement, the global top 10 pharmaceutical partner will utilize ASOs derived from Secarna's proprietary LNAplusTM platform in support of anti-cancer therapies the partner is developing and commercializing. Financial terms and the name of the partner were not disclosed. The LNAplusTM platform has been validated through numerous internal projects as well as multiple academic and industry collaborations such as with Firebrand Therapeutics, Lipigon Pharmaceuticals, and Met P Pharma.

"This first agreement with a large global pharmaceutical partner is a major milestone for Secarna and a crucial step in paving the path for a new generation of anti-cancer therapeutics," said Jonas Renz, Managing Director and Co-founder of Secarna Pharmaceuticals. "The agreement is a further testament to our LNAplusTM approach of developing highly specific, safety-optimized and efficacious antisense oligonucleotide therapies for challenging targets."

About Secarna's Proprietary Drug Discovery Platform, LNAplusTM

Secarna's proprietary third-generation antisense oligonucleotide (ASO) platform, LNAplusTM, which encompasses all aspects of drug discovery and pre-clinical development, enables the Company to discover novel antisense-based therapies for challenging or currently undruggable targets. Secarna's platform and ASOs have previously been validated by numerous in-house projects as well as in several academic and industry collaborations. With over 15 development programs focusing on targets and indications such as immuno-oncology, immunology, antiviral, fibrotic diseases, ophthalmology, neurodegenerative diseases and cardiometabolic diseases, where antisense-based approaches have clear benefits compared to other therapeutic modalities, Secarna is the leading European antisense drug discovery and development company.

About Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna's mission is to maximize the performance and output of its proprietary LNAplusTM antisense oligonucleotide platform to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets. www.secarna.com

 

Contact

Jonas Renz
Managing Director and Co-founder
Jonas.Renz@secarna.com

Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0)89 215 46 375

For media enquiries:

Anne Hennecke
MC Services AG
anne.hennecke@mc-services.eu
Tel.: +49 (0)211.52 92 52 22



10.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

Media and Games Invest plc

Original-Research: Media and Games Invest plc (von GBC AG): Kaufen

18. November 2019